In vitro ADME screening during the lead optimization stage of drug discovery positively impacts drug candidate selection with an enhanced probability of success in clinical trials. Since most new drug candidates fail during preclinical and clinical development, and the late stage of the drug development cycle can be a lengthy and costly process, any means of identifying drug candidates with optimized ADME and pharmacokinetics properties in the discovery stage will have a significant impact on the drug discovery process overall.
Q2 Solutions’ highly automated in vitro ADME laboratory partners with small, mid and large pharmaceutical customers around the world to perform large scale ADME screening assays using in-house or client-customized protocols. Our rapid ADME assay development turnaround time enables parallel optimization of the ADME properties of your chemical platform, alongside your potency and selectivity targets, thereby enabling you to make important decisions about your potential candidates.
Partner with us for your preclinical ADME screening needs to realize:
Our experienced scientists perform a range of high-throughput screening services, routinely conducting industry-standard in vitro ADME assays and continuously developing novel in vitro assays to address current metabolism issues and the evolving needs of our customers.
2019 | |||
Tier 1 Screening Suite | Assay Requests | Average TAT (days) | Samples Analyzed |
Solubility: Turbidimetric | >7,600 | <2 | >91,000 |
Permeability: MDCK Bidirectional | >5,600 | <4 | >96,000 |
Microsome Stability: Single Time Point | >18,000 | <3 | >103,000 |
Microsome Stability: Intrinsic Clearance | >3,900 | <4 | >27,000 |
Intrinsic Clearance Hepatocytes | >8,500 | <4 | >129,000 |
P450 Inhibition: Reversible Single Point | >8,200 | <2 | >16,000 |
P450 Inhibition: Reversible IC50 | >700 | <7 | >6,100 |
Blood to Plasma Ratio | >950 | <12 | >73,000 |
Protein Binding (Plasma, Tissue, Microsome) | >12,000 | <4 | >202,000 |
The initiation of early ADME screening dramatically decreases the proportion of compounds failing in clinical trials. Our preclinical ADME screening services help customers eliminate weak drug candidates prior to clinical development, thereby helping them to focus their resources on potential drug candidates so that the right drugs get to the right patients faster and more efficiently.
Capacity and on-time delivery is critical to this process:
In this podcast Barry Jones (Director, LC–MS Biologics and Biomarkers at Q² Solutions) and Adriane Spytko (Manager, LC–MS Biologics at Q² Solutions; both NY, USA) discuss hybrid assays using both...
The increasing complexity of large molecule therapeutics has driven the need for additional approaches to quantitation in regulated bioanalysis where challenges with traditional ligand binding assays...
Q2 Solutions offers tailored and comprehensive small molecule bioanalytical and ADME laboratory services. We combine scientific excellence, high-quality project management, and outstanding delivery...